Natixis Advisors LLC Has $236.99 Million Position in Abbott Laboratories $ABT

Natixis Advisors LLC lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,769,356 shares of the healthcare product maker’s stock after acquiring an additional 39,569 shares during the period. Natixis Advisors LLC’s holdings in Abbott Laboratories were worth $236,987,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Carr Financial Group Corp grew its holdings in Abbott Laboratories by 2.0% in the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after purchasing an additional 76 shares during the period. Tortoise Investment Management LLC raised its stake in shares of Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after buying an additional 77 shares during the period. Gemmer Asset Management LLC lifted its position in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after buying an additional 78 shares in the last quarter. Nia Impact Advisors LLC grew its stake in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after acquiring an additional 79 shares during the period. Finally, Global Financial Private Client LLC increased its holdings in Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after acquiring an additional 79 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Activity

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,055 shares of company stock valued at $353,097. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $109.74 on Friday. The firm has a 50-day simple moving average of $116.09 and a two-hundred day simple moving average of $124.63. The stock has a market cap of $190.69 billion, a PE ratio of 29.50, a P/E/G ratio of 1.74 and a beta of 0.74. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $139.15. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the business posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ABT. Royal Bank Of Canada reduced their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Sanford C. Bernstein cut their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Raymond James Financial reduced their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Leerink Partners lowered their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Finally, The Goldman Sachs Group dropped their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.